Board Member
Biocryst Pharmaceuticals Inc (BCRX)Equibles does not estimate personal net worth.
Get an email with a short summary when Biocryst Pharmaceuticals Inc publishes a filing, an earnings call transcript or a press release.
Get BCRX alertsJon Stonehouse is recorded as Board Member at Biocryst Pharmaceuticals Inc (BCRX) since January 1, 2007. Biocryst Pharmaceuticals Inc reported in an 8-K filed July 31, 2025 that Jon Stonehouse retired as President and Chief Executive Officer, effective December 31, 2025. Jon Stonehouse has spoken on 23 earnings calls across 1 company, most recently for Biocryst Pharmaceuticals Inc on October 14, 2025. Biocryst Pharmaceuticals Inc is classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. Other leadership on record at Biocryst Pharmaceuticals Inc includes Charles Gayer (CEO and Board Member), Charlie Gayer (CEO and Board Member), Vincent J. Milano (Chairman and Board Member) and 7 others.
“On July 25, 2025, Jon Stonehouse, President and Chief Executive Officer of BioCryst Pharmaceuticals, Inc., a Delaware corporation (the “Company”), notified the Company’s Board of Directors (the “Board”) of his intention to retire from his role as President and Chief Executive Officer of the Company, effective December 31, 2025.”
“We are very pleased to report yet another strong quarter for the year. Starting with ORLADEYO, we continue to see strong revenue growth year-over-year on a growing revenue base, well on our way to $1 billion at peak.”
“Q2 was another outstanding quarter of performance for BioCryst. For ORLADEYO, it was the best quarter since approval, both from a revenue and underlying new patient demand perspective.”
“We've started 2025 with another quarter of outstanding performance. As you will hear from Charlie in more detail, the U.S. commercial team made tremendous progress in moving patients on ORLADEYO from free drug to paid at a much faster rate than we expected.”
“We ended 2024 with the strongest execution and performance in the company's history. What's even more exciting is it happened across the company. For the full year 2024, Orladeo revenue year-over-year grew by 34%, and we added as many patients as we did in the first year of launch.”
“Our third quarter performance is remarkable on multiple fronts. First, growing ORLADEYO quarterly revenue year-over-year by nearly 36%, now four years in from approval, is amazing.”
2007-01-01–present
Start not stated–2025-12-31
Drug Manufacturers - Specialty & Generic · Healthcare
Board Member
2007-01-01–present
